January 1, 2003Platelets
Both the ADP receptors P2Y 1 and P2Y 12 , play a role in controlling shape change in human platelets
Why the study?
Do P2Y1, P2Y12, and P2X1 receptor antagonists inhibit ADP-induced platelet shape change in human platelets?
Population
Human platelets
Comparison
P2Y1 receptor antagonist, P2Y12 receptor… vs ADP or ADP + serotonin (5HT) without antagonists
Design
Preclinical
Authors
Discussion
Loading...
Member takes
Implication
Does not support clinical adoption; hypothesis-generating for P2Y receptor roles in human platelet activation.
Structured PICO
Do P2Y1, P2Y12, and P2X1 receptor antagonists inhibit ADP-induced platelet shape change in human platelets?
P
Population
Human platelets
I
Intervention
P2Y1 receptor antagonist (MRS 2179), P2Y12 receptor antagonist (AR-C69931MX), and P2X1 receptor antagonist (TNP-ATP)
C
Comparator
ADP or ADP + serotonin (5HT) without antagonists
O
Outcome
Platelet shape change (PSC) assessed by measuring median platelet volume (MPV) using a high-resolution channelyzersurrogate
Both P2Y1 and P2Y12 receptors are involved in ADP-induced platelet shape change, an early phase of platelet activation.
Cite This Study
Jagroop et al. (2003) studied this question.